Table 13.
Country | Ampicillin | Azithromycin | Cefotaxime | Ceftazidime | Chloramphenicol | Ciprofloxacin | Colistina | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
Belgium | 183 | 42.1 | 183 | 0.5 | 183 | 1.1 | 183 | 1.1 | 183 | 6.0 | 183 | 4.4 | 183 | 1.1 |
Croatia | 31 | 48.4 | 31 | 0 | 31 | 0 | 31 | 0 | 31 | 12.9 | 31 | 0 | 31 | 0 |
Cyprus | 4 | 75 | 4 | 25.0 | 4 | 0 | 4 | 0 | 4 | 25.0 | 4 | 25 | 4 | 0 |
Czech Republic | 23 | 26.1 | 23 | 0 | 23 | 4.3 | 23 | 4.3 | 23 | 4.3 | 23 | 0 | 23 | 0 |
Denmark | 78 | 35.9 | 78 | 1.3 | 78 | 0 | 78 | 0 | 78 | 5.1 | 78 | 0 | 78 | 1.3 |
Estonia | 10 | 20 | 10 | 0 | 10 | 0 | 10 | 0 | 10 | 0 | 10 | 0 | 10 | 0 |
France | 115 | 40.9 | 115 | 0 | 115 | 0 | 115 | 0 | 115 | 14.8 | 115 | 0.9 | 115 | 1.7 |
Germany | 51 | 56.9 | 51 | 5.9 | 51 | 3.9 | 51 | 3.9 | 51 | 17.6 | 51 | 2 | 51 | 0 |
Hungary | 8 | 87.5 | 8 | 0 | 8 | 0 | 8 | 0 | 8 | 25.0 | 8 | 12.5 | 8 | 0 |
Latvia | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 |
Malta | 16 | 18.8 | 16 | 0 | 16 | 0 | 16 | 0 | 16 | 6.3 | 16 | 0 | 16 | 6.3 |
Poland | 10 | 60.0 | 10 | 0 | 10 | 0 | 10 | 0 | 10 | 20.0 | 10 | 40.0 | 10 | 0 |
Portugal | 48 | 52.1 | 48 | 37.5 | 48 | 4.2 | 48 | 4.2 | 48 | 20.8 | 48 | 8.3 | 48 | 6.3 |
Romania | 23 | 47.8 | 23 | 0 | 23 | 0 | 23 | 0 | 23 | 4.3 | 23 | 8.7 | 23 | 0 |
Slovakia | 11 | 27.3 | 11 | 0 | 11 | 0 | 11 | 0 | 11 | 0 | 11 | 0 | 11 | 0 |
Spain | 128 | 54.7 | 128 | 1.6 | 128 | 0.8 | 128 | 0 | 128 | 19.5 | 128 | 7 | 128 | 0.8 |
United Kingdom | 9 | 33.3 | 9 | 0 | 9 | 0 | 9 | 0 | 9 | 11.1 | 9 | 11.1 | 9 | 0 |
Total (17 MSs) | 750 | 44.7 | 750 | 3.5 | 750 | 1.1 | 750 | 0.9 | 750 | 11.9 | 750 | 4.3 | 750 | 1.3 |
Iceland | 7 | 28.6 | 7 | 0 | 7 | 0 | 7 | 0 | 7 | 0 | 7 | 0 | 7 | 0 |
Country | Gentamicin | Nalidixic acid | Sulfamethoxazole | Tetracycline | Tigecyclineb | Trimethoprim | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
Belgium | 183 | 0.5 | 183 | 3.8 | 183 | 40.4 | 183 | 33.9 | 183 | 1.6 | 183 | 16.9 |
Croatia | 31 | 3.2 | 31 | 0 | 31 | 35.5 | 31 | 41.9 | 31 | 0 | 31 | 16.1 |
Cyprus | 4 | 50 | 4 | 0 | 4 | 100 | 4 | 100 | 4 | 0 | 4 | 75.0 |
Czech Republic | 23 | 0 | 23 | 0 | 23 | 21.7 | 23 | 13.0 | 23 | 0 | 23 | 4.3 |
Denmark | 78 | 0 | 78 | 0 | 78 | 38.5 | 78 | 30.8 | 78 | 0 | 78 | 10.3 |
Estonia | 10 | 0 | 10 | 0 | 10 | 20 | 10 | 20 | 10 | 0 | 10 | 10 |
France | 115 | 1.7 | 115 | 0.9 | 115 | 53.9 | 115 | 54.8 | 115 | 0 | 115 | 7.8 |
Germany | 51 | 3.9 | 51 | 0 | 51 | 56.9 | 51 | 62.7 | 51 | 3.9 | 51 | 17.6 |
Hungary | 8 | 0 | 8 | 12.5 | 8 | 75 | 8 | 75 | 8 | 0 | 8 | 0 |
Latvia | 2 | 0 | 2 | 0 | 2 | 100 | 2 | 100 | 2 | 0 | 2 | 0 |
Malta | 16 | 0 | 16 | 0 | 16 | 62.5 | 16 | 25.0 | 16 | 0 | 16 | 0 |
Poland | 10 | 0 | 10 | 30.0 | 10 | 70.0 | 10 | 60.0 | 10 | 0 | 10 | 10.0 |
Portugal | 48 | 0 | 48 | 4.2 | 48 | 70.8 | 48 | 83.3 | 48 | 20.8 | 48 | 50.0 |
Romania | 23 | 4.3 | 23 | 4.3 | 23 | 30.4 | 23 | 34.8 | 23 | 0 | 23 | 21.7 |
Slovakia | 11 | 0 | 11 | 0 | 11 | 27.3 | 11 | 18.2 | 11 | 0 | 11 | 9.1 |
Spain | 128 | 0.8 | 128 | 6.3 | 128 | 57.8 | 128 | 73.4 | 128 | 3.9 | 128 | 21.1 |
United Kingdom | 9 | 11.1 | 9 | 11.1 | 9 | 44.4 | 9 | 33.3 | 9 | 0 | 9 | 11.1 |
Total (17 MSs) | 750 | 1.5 | 750 | 3.2 | 750 | 48.5 | 750 | 49.1 | 750 | 2.7 | 750 | 16.8 |
Iceland | 7 | 0 | 7 | 0 | 7 | 28.6 | 7 | 28.6 | 7 | 0 | 7 | 28.6 |
All Salmonella isolates tested were susceptible to meropenem. N: number of isolates tested; % Res: percentage of microbiologically resistant isolates; –: no information available; MSs: Member States.
A number of colistin‐resistant isolates are undergoing testing for the presence of mcr‐1 gene. The reported occurrence of colistin resistance is unlikely to equate to the occurrence of mcr‐1. ECOFF applied 2 mg/L.
ECOFF applied 1 mg/L.